Pigmentary retinopathy associated with immune therapy for advanced cutaneous melanoma.

Author: BorooahShyamanga, DanielsGregory A, LinAndrew C, ParkSoo J

Paper Details 
Original Abstract of the Article :
PURPOSE: To describe a case of bilateral retinal pigmentary changes in the setting of immune checkpoint inhibitor therapy (ICIT). OBSERVATIONS: A 69-year-old man with a history of advanced cutaneous melanoma was started on combination ICIT with nivolumab and ipilimumab and stereotactic body radiati...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149182/

データ提供:米国国立医学図書館(NLM)

Navigating the Desert of Immune Therapy: Retinal Pigmentary Changes Emerge as a Potential Side Effect

Immune checkpoint inhibitor therapy (ICIT) has revolutionized cancer treatment, offering new hope in the desert of cancer therapies. This study explores a rare side effect of ICIT, retinal pigmentary changes, in a patient with advanced cutaneous melanoma. The authors describe the case of a patient who developed bilateral retinal pigmentary changes after receiving combination ICIT with nivolumab and ipilimumab. The findings suggest that retinal pigmentary changes might be a potential side effect of ICIT, highlighting the importance of monitoring for ocular complications.

A New Frontier: Exploring the Potential Side Effects of ICIT

This case report offers valuable insights into the potential side effects of ICIT. The findings highlight the importance of vigilant monitoring for ocular complications, especially in patients receiving ICIT for advanced melanoma.

A Call for Vigilance: Monitoring for Ocular Side Effects of ICIT

This research underscores the need for ongoing vigilance in monitoring for potential side effects of ICIT, particularly ocular complications. The findings emphasize the importance of a multidisciplinary approach to patient care, involving ophthalmologists and oncologists to ensure the best possible outcomes for patients receiving this groundbreaking therapy.

Dr. Camel's Conclusion

This case report sheds light on a rare but potentially significant side effect of ICIT, retinal pigmentary changes. The findings highlight the importance of vigilance in monitoring for ocular complications in patients receiving ICIT, especially those with advanced melanoma. This research underscores the need for a collaborative approach to patient care, involving ophthalmologists and oncologists to ensure the best possible outcomes for patients undergoing ICIT.

Date :
  1. Date Completed n.d.
  2. Date Revised 2023-05-04
Further Info :

Pubmed ID

37131528

DOI: Digital Object Identifier

PMC10149182

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.